ES2193875A1 - Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. - Google Patents

Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Info

Publication number
ES2193875A1
ES2193875A1 ES200200813A ES200200813A ES2193875A1 ES 2193875 A1 ES2193875 A1 ES 2193875A1 ES 200200813 A ES200200813 A ES 200200813A ES 200200813 A ES200200813 A ES 200200813A ES 2193875 A1 ES2193875 A1 ES 2193875A1
Authority
ES
Spain
Prior art keywords
medicaments
preparation
compounds
general formula
benzoxazinone derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200200813A
Other languages
English (en)
Other versions
ES2193875B2 (es
Inventor
Antonio Torrens-Jover
Jose Aurelio Castrillo-Perez
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to ES200200813A priority Critical patent/ES2193875B2/es
Priority to US10/407,343 priority patent/US7056914B2/en
Priority to ARP030101184A priority patent/AR039256A1/es
Priority to EP03718741A priority patent/EP1497285B1/en
Priority to PCT/EP2003/003629 priority patent/WO2003084952A1/en
Priority to IL16444203A priority patent/IL164442A0/xx
Priority to AU2003222804A priority patent/AU2003222804A1/en
Priority to RU2004133041/04A priority patent/RU2004133041A/ru
Priority to KR10-2004-7016130A priority patent/KR20050008679A/ko
Priority to CN038128853A priority patent/CN1659164A/zh
Priority to BR0309083-3A priority patent/BR0309083A/pt
Priority to JP2003582149A priority patent/JP2005529866A/ja
Priority to MXPA04009889A priority patent/MXPA04009889A/es
Priority to US10/409,235 priority patent/US7041665B2/en
Priority to AT03718741T priority patent/ATE489382T1/de
Priority to ES03718741T priority patent/ES2356815T3/es
Priority to PL03372537A priority patent/PL372537A1/xx
Priority to NZ536167A priority patent/NZ536167A/en
Priority to DE60335094T priority patent/DE60335094D1/de
Priority to ARP030101235A priority patent/AR048567A1/es
Priority to CA002481701A priority patent/CA2481701A1/en
Priority to DE60303440T priority patent/DE60303440T2/de
Priority to SI200330210T priority patent/SI1500654T1/sl
Priority to DK03712152T priority patent/DK1500654T3/da
Priority to PT03712152T priority patent/PT1500654E/pt
Priority to EP03712152A priority patent/EP1500654B1/en
Priority to PCT/ES2003/000162 priority patent/WO2003084939A1/es
Priority to AT03712152T priority patent/ATE316966T1/de
Priority to AU2003216934A priority patent/AU2003216934A1/en
Priority to ES03712152T priority patent/ES2258219T3/es
Priority to UA20041109155A priority patent/UA79460C2/uk
Publication of ES2193875A1 publication Critical patent/ES2193875A1/es
Priority to HR20040919A priority patent/HRP20040919A2/hr
Priority to IS7491A priority patent/IS7491A/is
Priority to EC2004005353A priority patent/ECSP045353A/es
Priority to MA27902A priority patent/MA27692A1/fr
Priority to TNP2004000203A priority patent/TNSN04203A1/en
Priority to NO20044322A priority patent/NO20044322L/no
Priority to ZA200408275A priority patent/ZA200408275B/en
Application granted granted Critical
Publication of ES2193875B2 publication Critical patent/ES2193875B2/es
Priority to HK05102067.9A priority patent/HK1069820A1/xx
Priority to US11/338,363 priority patent/US7514429B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Derivados de benzoxazinona, su preparación y su aplicación como medicamentos. La presente invención se refiere a nuevos compuestos de fórmula general (I), en la cual: R1 representa hidrógeno, halógeno, alcoxilo o un radical alquilo C1-C4; R2 representa hidrógeno, un radical alquilo C1-C4, un radical fenilo, un radical bencilo o junto con R3 puede formar parte de un heterociclo de cinco o seis miembros; R3 representa anillo bicíclico, anillo tricíclico, fenilo sustituido o fenilo sustituido por una cadena hidrocarbonada que junto con R2 forma parte de un heterociclo nitrogenado de cinco o seis miembros; A representa -CHR4- o -CHR4-CH2- R4 representa hidrógeno, un radical alquilo C1-C4 o un radical fenilo; o una de sus sales fisiológicamente aceptables; así como a sus sales fisiológicamente aceptables, a los procedimientos para su preparación, a su aplicación como medicamentos para la prevención o el tratamiento de varios trastornos del Sistema Nervioso Central, y en particular la obesidad, la ansiedad, la depresión, los trastornos cognitivos y otros trastornos mediados por el receptor NPY5 en mamíferos, y a las composiciones farmacéuticas que los contienen.
ES200200813A 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. Expired - Fee Related ES2193875B2 (es)

Priority Applications (40)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ARP030101184A AR039256A1 (es) 2002-04-09 2003-04-04 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos
US10/407,343 US7056914B2 (en) 2002-04-09 2003-04-04 Benzoxazinone-derived compounds, their preparation and use as medicaments
BR0309083-3A BR0309083A (pt) 2002-04-09 2003-04-08 Compostos derivados de benzoxazinona, sua preparação e uso como medicamentos
IL16444203A IL164442A0 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparationand use as medicaments
AU2003222804A AU2003222804A1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation and use as medicaments
RU2004133041/04A RU2004133041A (ru) 2002-04-09 2003-04-08 Производные бензоксазинона, их получение и применение в качестве лекарственных средств
KR10-2004-7016130A KR20050008679A (ko) 2002-04-09 2003-04-08 벤조옥사지논-유도 화합물, 그 제조방법 및 약제로서의 용도
CN038128853A CN1659164A (zh) 2002-04-09 2003-04-08 苯并噁嗪酮衍生的化合物、它们的制备方法和作为药物的用途
PCT/EP2003/003629 WO2003084952A1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation und use as medicaments
JP2003582149A JP2005529866A (ja) 2002-04-09 2003-04-08 ベンゾキサジノン誘導化合物、その調製および薬剤としての使用
MXPA04009889A MXPA04009889A (es) 2002-04-09 2003-04-08 Compuestos derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
US10/409,235 US7041665B2 (en) 2002-04-09 2003-04-08 Benzoxazinone derivatives, their preparation and use as medicaments
AT03718741T ATE489382T1 (de) 2002-04-09 2003-04-08 Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel
ES03718741T ES2356815T3 (es) 2002-04-09 2003-04-08 Derivados de benzoxazinona, su preparación y su aplicación como medicamentos.
PL03372537A PL372537A1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation und use as medicaments
NZ536167A NZ536167A (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation and use as medicaments
DE60335094T DE60335094D1 (de) 2002-04-09 2003-04-08 Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel
ARP030101235A AR048567A1 (es) 2002-04-09 2003-04-08 Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
CA002481701A CA2481701A1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation and use as medicaments
EP03718741A EP1497285B1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation und use as medicaments
DK03712152T DK1500654T3 (da) 2002-04-09 2003-04-09 Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler
SI200330210T SI1500654T1 (sl) 2002-04-09 2003-04-09 Benzoksazinonski derivati, priprava in uporaba le-teh kot zdravila
DE60303440T DE60303440T2 (de) 2002-04-09 2003-04-09 Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
PT03712152T PT1500654E (pt) 2002-04-09 2003-04-09 Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
EP03712152A EP1500654B1 (en) 2002-04-09 2003-04-09 Benzoxazinone derivatives, the preparation and use thereof as medicaments
PCT/ES2003/000162 WO2003084939A1 (es) 2002-04-09 2003-04-09 Derivados de benzoxazinona, su preparación y su aplicación como medicamentos
AT03712152T ATE316966T1 (de) 2002-04-09 2003-04-09 Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
AU2003216934A AU2003216934A1 (en) 2002-04-09 2003-04-09 Benzoxazinone derivatives, the preparation and use thereof as medicaments
ES03712152T ES2258219T3 (es) 2002-04-09 2003-04-09 Derivados de benzoxazinona, su preparacion y su uso como medicamentos.
UA20041109155A UA79460C2 (en) 2002-04-09 2003-08-04 Benzoxazinone derived compounds, method for their preparation, intermediate, medicaments containing these compounds
HR20040919A HRP20040919A2 (en) 2002-04-09 2004-10-05 Benzoxazinone-derived compounds, their preparationund use as medicaments
IS7491A IS7491A (is) 2002-04-09 2004-10-06 Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf
EC2004005353A ECSP045353A (es) 2002-04-09 2004-10-08 Derivados de benzoxazinona, su preparación y aplicación como medicamentos
MA27902A MA27692A1 (fr) 2002-04-09 2004-10-08 Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
TNP2004000203A TNSN04203A1 (en) 2002-04-09 2004-10-08 Benzoxazinone-derived compounds, their preparation and use as medicaments
NO20044322A NO20044322L (no) 2002-04-09 2004-10-12 Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
ZA200408275A ZA200408275B (en) 2002-04-09 2004-10-13 Benzoxazinone-derived compounds their preparation and use as medicaments
HK05102067.9A HK1069820A1 (en) 2002-04-09 2005-03-09 Benzoxazinone-derived compounds, their preparation und use as medicaments
US11/338,363 US7514429B2 (en) 2002-04-09 2006-01-24 Benzoxazinone-derived compounds, their preparation and use as medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Publications (2)

Publication Number Publication Date
ES2193875A1 true ES2193875A1 (es) 2003-11-01
ES2193875B2 ES2193875B2 (es) 2005-03-01

Family

ID=28686085

Family Applications (3)

Application Number Title Priority Date Filing Date
ES200200813A Expired - Fee Related ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES03718741T Expired - Lifetime ES2356815T3 (es) 2002-04-09 2003-04-08 Derivados de benzoxazinona, su preparación y su aplicación como medicamentos.
ES03712152T Expired - Lifetime ES2258219T3 (es) 2002-04-09 2003-04-09 Derivados de benzoxazinona, su preparacion y su uso como medicamentos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES03718741T Expired - Lifetime ES2356815T3 (es) 2002-04-09 2003-04-08 Derivados de benzoxazinona, su preparación y su aplicación como medicamentos.
ES03712152T Expired - Lifetime ES2258219T3 (es) 2002-04-09 2003-04-09 Derivados de benzoxazinona, su preparacion y su uso como medicamentos.

Country Status (29)

Country Link
US (3) US7056914B2 (es)
EP (2) EP1497285B1 (es)
JP (1) JP2005529866A (es)
KR (1) KR20050008679A (es)
CN (1) CN1659164A (es)
AR (2) AR039256A1 (es)
AT (2) ATE489382T1 (es)
AU (2) AU2003222804A1 (es)
BR (1) BR0309083A (es)
CA (1) CA2481701A1 (es)
DE (2) DE60335094D1 (es)
DK (1) DK1500654T3 (es)
EC (1) ECSP045353A (es)
ES (3) ES2193875B2 (es)
HK (1) HK1069820A1 (es)
HR (1) HRP20040919A2 (es)
IL (1) IL164442A0 (es)
IS (1) IS7491A (es)
MA (1) MA27692A1 (es)
MX (1) MXPA04009889A (es)
NO (1) NO20044322L (es)
NZ (1) NZ536167A (es)
PL (1) PL372537A1 (es)
PT (1) PT1500654E (es)
RU (1) RU2004133041A (es)
TN (1) TNSN04203A1 (es)
UA (1) UA79460C2 (es)
WO (2) WO2003084952A1 (es)
ZA (1) ZA200408275B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
WO2005090340A1 (ja) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. ピペリジン－１－カルボキサミド誘導体
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
CA2590433C (en) * 2005-03-21 2012-09-18 The Procter & Gamble Company Multi-phase personal care composition comprising visually distinct phases
MX2007012898A (es) * 2005-04-13 2007-12-10 Procter & Gamble Composicion de fases multiples estructurada para el cuidado personal que comprende surfactantes anionicos ramificados.
US7820609B2 (en) 2005-04-13 2010-10-26 The Procter & Gamble Company Mild, structured, multi-phase personal cleansing compositions comprising density modifiers
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
US20120015009A9 (en) * 2005-06-07 2012-01-19 The Procter & Gamble Company Multi-phased personal care composition comprising a blooming perfume composition
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
CN101326106A (zh) * 2005-12-08 2008-12-17 宝洁公司 包括邻近表面形貌定位的模内标签的容器
US20070167338A1 (en) * 2006-01-09 2007-07-19 Mchugh Colin M Multiphase personal care compositions comprising beads
US8104616B2 (en) 2006-02-11 2012-01-31 The Procter & Gamble Company Clamshell package for holding and displaying consumer products
US8153144B2 (en) * 2006-02-28 2012-04-10 The Proctor & Gamble Company Stable multiphase composition comprising alkylamphoacetate
WO2008020455A2 (en) * 2006-08-14 2008-02-21 Council Of Scientific & Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
US20090028809A1 (en) * 2007-07-27 2009-01-29 Jonathan Robert Cetti Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials
US20090029900A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with distinct fragrance characters
US20090028808A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents
US7733945B2 (en) * 2008-03-18 2010-06-08 On-Ramp Wireless, Inc. Spread spectrum with doppler optimization
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
CN110684043B (zh) * 2019-08-13 2022-09-06 温州大学 一种c-n轴手性芳胺化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002405A1 (en) * 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
WO2001044213A1 (en) * 1999-12-17 2001-06-21 Astrazeneca Ab New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028397A1 (en) 1994-04-14 1995-10-26 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
EP0955293B1 (en) 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
AU6309698A (en) 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
ATE284861T1 (de) 1998-10-07 2005-01-15 Ortho Mcneil Pharm Inc N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
JP2003507424A (ja) 1999-08-26 2003-02-25 ブリストル−マイヤーズ スクイブ カンパニー Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
AU2002323787B2 (en) * 2001-08-07 2008-04-24 Banyu Pharmaceutical Co., Ltd. Spiro compounds
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002405A1 (en) * 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
WO2001044213A1 (en) * 1999-12-17 2001-06-21 Astrazeneca Ab New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMS, P.D. et al. Nonpeptide oxytocin antagonists: Analogs of L-371.257 with improved potency. Bioorganic & Medicinal Chemistry Letters, 1999, Vol. 9, pßginas 1311-1316, todo el documento. *

Also Published As

Publication number Publication date
PL372537A1 (en) 2005-07-25
RU2004133041A (ru) 2005-09-10
EP1500654A1 (en) 2005-01-26
TNSN04203A1 (en) 2007-03-12
WO2003084952A1 (en) 2003-10-16
AR048567A1 (es) 2006-05-10
BR0309083A (pt) 2005-04-19
ES2193875B2 (es) 2005-03-01
DE60303440T2 (de) 2006-10-26
US7514429B2 (en) 2009-04-07
CA2481701A1 (en) 2003-10-16
US20040058920A1 (en) 2004-03-25
NO20044322L (no) 2004-10-12
US7056914B2 (en) 2006-06-06
JP2005529866A (ja) 2005-10-06
ATE489382T1 (de) 2010-12-15
AU2003216934A1 (en) 2003-10-20
US7041665B2 (en) 2006-05-09
DK1500654T3 (da) 2006-06-06
ATE316966T1 (de) 2006-02-15
AR039256A1 (es) 2005-02-16
US20040067941A1 (en) 2004-04-08
MA27692A1 (fr) 2006-01-02
US20060128701A1 (en) 2006-06-15
ZA200408275B (en) 2006-04-26
IS7491A (is) 2004-10-06
HRP20040919A2 (en) 2005-04-30
IL164442A0 (en) 2005-12-18
ECSP045353A (es) 2005-01-28
DE60335094D1 (de) 2011-01-05
NZ536167A (en) 2006-06-30
KR20050008679A (ko) 2005-01-21
ES2258219T3 (es) 2006-08-16
DE60303440D1 (de) 2006-04-13
EP1497285B1 (en) 2010-11-24
PT1500654E (pt) 2006-06-30
CN1659164A (zh) 2005-08-24
AU2003222804A1 (en) 2003-10-20
MXPA04009889A (es) 2005-08-16
WO2003084939A1 (es) 2003-10-16
EP1497285A1 (en) 2005-01-19
UA79460C2 (en) 2007-06-25
EP1500654B1 (en) 2006-02-01
ES2356815T3 (es) 2011-04-13
HK1069820A1 (en) 2005-06-03

Similar Documents

Publication Publication Date Title
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
AU2003298094A1 (en) Medicinal arylethanolamine compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
TW200611695A (en) Pyrrolopyridine derivatives
GB0112348D0 (en) Compounds
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
TW200626158A (en) Naphthaline derivatives
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
TW200509907A (en) Indol-6-yl sulfonamide derivatives, their preparation and their use in medicaments
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
MX2009005507A (es) Derivados de espiro-piperidina.
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
MX2009006454A (es) Derivados de espiro-piperidina.
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2193875B2

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20170216